Global injectable nanomedicines market is expected to grow at a CAGR of 16.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic diseases such as cancer and cardiovascular disease, which are major drivers for the growth of this market. In addition, technological advancements in nanomedicine manufacturing processes have led to improved product quality and reduced production costs.
The global injectable nanomedicines market has been segmented on the basis of type into liposomes, micelles, nanoparticles and polymeric nanoparticles; by application into cancer, central nervous system disease (CNS), cardiovascular disease (CVD) and infection control; and by region into North America (NA), Latin America (LA), Europe (EU), Asia Pacific (APAC) and Middle East & Africa (MEA).
- The increasing prevalence of chronic diseases such as cancer and diabetes is driving the growth of the injectable nanomedicines market globally.
- Injectable nanomedicines are used for various therapeutic purposes such as treatment of cancer, diabetes, and cardiovascular diseases among others which are also driving the growth of this market globally.
- Increasing awareness about injectable nanomedicines among physicians and patients is also contributing to the growth of this market globally.
- Increasing government funding for research in developing countries such as China and India is also contributing to the growth of this market.
Industry Growth Insights published a new data on “Injectable Nanomedicines Market”. The research report is titled “Injectable Nanomedicines Market research by Types (Liposomes, Micelles, Nanocrystals, Polymeric Nanoparticles, Other), By Applications (Cancer, Central Nervous System Disease, Cardiovascular Disease, Infection Control, Other), By Players/Companies Merck, Lupin, Pacira Pharmaceuticals, Celgene Pharmaceutical, Amgen, Janssen Biotech, Pfizer, Hoffmann-La Roche, Teva Pharmaceutical Industries, Bausch & Lomb”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Injectable Nanomedicines Market Research Report
By Type
Liposomes, Micelles, Nanocrystals, Polymeric Nanoparticles, Other
By Application
Cancer, Central Nervous System Disease, Cardiovascular Disease, Infection Control, Other
By Companies
Merck, Lupin, Pacira Pharmaceuticals, Celgene Pharmaceutical, Amgen, Janssen Biotech, Pfizer, Hoffmann-La Roche, Teva Pharmaceutical Industries, Bausch & Lomb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Injectable Nanomedicines Market Report Segments:
The global Injectable Nanomedicines market is segmented on the basis of:
Types
Liposomes, Micelles, Nanocrystals, Polymeric Nanoparticles, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Central Nervous System Disease, Cardiovascular Disease, Infection Control, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Lupin
- Pacira Pharmaceuticals
- Celgene Pharmaceutical
- Amgen
- Janssen Biotech
- Pfizer
- Hoffmann-La Roche
- Teva Pharmaceutical Industries
- Bausch & Lomb
Highlights of The Injectable Nanomedicines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liposomes
- Micelles
- Nanocrystals
- Polymeric Nanoparticles
- Other
- By Application:
- Cancer
- Central Nervous System Disease
- Cardiovascular Disease
- Infection Control
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Injectable Nanomedicines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Injectable nanomedicines are medications that are administered by injection. They are made up of small, self-propelled particles that can travel through the body and interact with cells to deliver their therapeutic payload. Injectable nanomedicines have the potential to improve patient care by providing faster and more effective treatment for a variety of diseases.
Some of the major players in the injectable nanomedicines market are Merck, Lupin, Pacira Pharmaceuticals, Celgene Pharmaceutical, Amgen, Janssen Biotech, Pfizer, Hoffmann-La Roche, Teva Pharmaceutical Industries, Bausch & Lomb.
The injectable nanomedicines market is expected to grow at a compound annual growth rate of 16.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Injectable Nanomedicines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Injectable Nanomedicines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Injectable Nanomedicines Market - Supply Chain
4.5. Global Injectable Nanomedicines Market Forecast
4.5.1. Injectable Nanomedicines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Injectable Nanomedicines Market Size (000 Units) and Y-o-Y Growth
4.5.3. Injectable Nanomedicines Market Absolute $ Opportunity
5. Global Injectable Nanomedicines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Injectable Nanomedicines Market Size and Volume Forecast by Type
5.3.1. Liposomes
5.3.2. Micelles
5.3.3. Nanocrystals
5.3.4. Polymeric Nanoparticles
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Injectable Nanomedicines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Injectable Nanomedicines Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Central Nervous System Disease
6.3.3. Cardiovascular Disease
6.3.4. Infection Control
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Injectable Nanomedicines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Injectable Nanomedicines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Injectable Nanomedicines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Injectable Nanomedicines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Injectable Nanomedicines Demand Share Forecast, 2019-2029
9. North America Injectable Nanomedicines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Injectable Nanomedicines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Injectable Nanomedicines Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Central Nervous System Disease
9.4.3. Cardiovascular Disease
9.4.4. Infection Control
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Injectable Nanomedicines Market Size and Volume Forecast by Type
9.7.1. Liposomes
9.7.2. Micelles
9.7.3. Nanocrystals
9.7.4. Polymeric Nanoparticles
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Injectable Nanomedicines Demand Share Forecast, 2019-2029
10. Latin America Injectable Nanomedicines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Injectable Nanomedicines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Injectable Nanomedicines Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Central Nervous System Disease
10.4.3. Cardiovascular Disease
10.4.4. Infection Control
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Injectable Nanomedicines Market Size and Volume Forecast by Type
10.7.1. Liposomes
10.7.2. Micelles
10.7.3. Nanocrystals
10.7.4. Polymeric Nanoparticles
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Injectable Nanomedicines Demand Share Forecast, 2019-2029
11. Europe Injectable Nanomedicines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Injectable Nanomedicines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Injectable Nanomedicines Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Central Nervous System Disease
11.4.3. Cardiovascular Disease
11.4.4. Infection Control
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Injectable Nanomedicines Market Size and Volume Forecast by Type
11.7.1. Liposomes
11.7.2. Micelles
11.7.3. Nanocrystals
11.7.4. Polymeric Nanoparticles
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Injectable Nanomedicines Demand Share, 2019-2029
12. Asia Pacific Injectable Nanomedicines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Injectable Nanomedicines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Injectable Nanomedicines Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Central Nervous System Disease
12.4.3. Cardiovascular Disease
12.4.4. Infection Control
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Injectable Nanomedicines Market Size and Volume Forecast by Type
12.7.1. Liposomes
12.7.2. Micelles
12.7.3. Nanocrystals
12.7.4. Polymeric Nanoparticles
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Injectable Nanomedicines Demand Share, 2019-2029
13. Middle East & Africa Injectable Nanomedicines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Injectable Nanomedicines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Injectable Nanomedicines Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Central Nervous System Disease
13.4.3. Cardiovascular Disease
13.4.4. Infection Control
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Injectable Nanomedicines Market Size and Volume Forecast by Type
13.7.1. Liposomes
13.7.2. Micelles
13.7.3. Nanocrystals
13.7.4. Polymeric Nanoparticles
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Injectable Nanomedicines Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Injectable Nanomedicines Market: Market Share Analysis
14.2. Injectable Nanomedicines Distributors and Customers
14.3. Injectable Nanomedicines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Lupin
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pacira Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celgene Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Amgen
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Janssen Biotech
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hoffmann-La Roche
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Teva Pharmaceutical Industries
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bausch & Lomb
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
